BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8978838)

  • 21. Non-covalent inhibitors of rhinovirus 3C protease.
    Baxter A; Chambers M; Edfeldt F; Edman K; Freeman A; Johansson C; King S; Morley A; Petersen J; Rawlins P; Spadola L; Thong B; Van de Poël H; Williams N
    Bioorg Med Chem Lett; 2011 Jan; 21(2):777-80. PubMed ID: 21183345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.
    Borthwick AD; Davies DE; Ertl PF; Exall AM; Haley TM; Hart GJ; Jackson DL; Parry NR; Patikis A; Trivedi N; Weingarten GG; Woolven JM
    J Med Chem; 2003 Oct; 46(21):4428-49. PubMed ID: 14521407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.
    Dragovich PS; Zhou R; Webber SE; Prins TJ; Kwok AK; Okano K; Fuhrman SA; Zalman LS; Maldonado FC; Brown EL; Meador JW; Patick AK; Ford CE; Brothers MA; Binford SL; Matthews DA; Ferre RA; Worland ST
    Bioorg Med Chem Lett; 2000 Jan; 10(1):45-8. PubMed ID: 10636240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.
    Patick AK; Brothers MA; Maldonado F; Binford S; Maldonado O; Fuhrman S; Petersen A; Smith GJ; Zalman LS; Burns-Naas LA; Tran JQ
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2267-75. PubMed ID: 15917520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors.
    Wang H; Xiao J; Gao D; Zhang X; Yan H; Gong Z; Sun T; Li S
    Bioorg Med Chem Lett; 2011 Feb; 21(3):1057-9. PubMed ID: 21215622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of the 2-methylene analogue of the HRV 3C protease inhibitor thysanone (2-carbathysanone).
    Schünemann K; Furkert DP; Choi EC; Connelly S; Fraser JD; Sperry J; Brimble MA
    Org Biomol Chem; 2014 Feb; 12(6):905-12. PubMed ID: 24346589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AG-7088 Pfizer.
    Witherell G
    Curr Opin Investig Drugs; 2000 Nov; 1(3):297-302. PubMed ID: 11249711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and evaluation of 2,2-dimethyl-1,3-dioxolane derivatives as human rhinovirus 3C protease inhibitors.
    Zhang Q; Cao R; Liu A; Lei S; Li Y; Yang J; Li S; Xiao J
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4061-4065. PubMed ID: 28778471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of in vitro peptide substrates for human rhinovirus-14 2A protease.
    Wang QM; Johnson RB; Sommergruber W; Shepherd TA
    Arch Biochem Biophys; 1998 Aug; 356(1):12-8. PubMed ID: 9681985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling.
    Kassem AF; Batran RZ; Abbas EMH; Elseginy SA; Shaheen MNF; Elmahdy EM
    Eur J Med Chem; 2019 Apr; 168():447-460. PubMed ID: 30844608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors.
    Fan SY; Zheng ZB; Mi CL; Zhou XB; Yan H; Gong ZH; Li S
    Bioorg Med Chem; 2009 Jan; 17(2):621-4. PubMed ID: 19091578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro.
    Jung E; Lee JY; Kim HJ; Ryu CK; Lee KI; Kim M; Lee CK; Go YY
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2533-2538. PubMed ID: 29866517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
    Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.
    Prior AM; Kim Y; Weerasekara S; Moroze M; Alliston KR; Uy RA; Groutas WC; Chang KO; Hua DH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6317-20. PubMed ID: 24125888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.
    Dragovich PS; Prins TJ; Zhou R; Johnson TO; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Hou X; Meador JW; Ferre RA; Worland ST
    Bioorg Med Chem Lett; 2002 Mar; 12(5):733-8. PubMed ID: 11858991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and evaluation of 9-deoxy analogues of (-)-thysanone, an inhibitor of HRV 3C protease.
    Young Jeong J; Sperry J; Taylor JA; Brimble MA
    Eur J Med Chem; 2014 Nov; 87():220-7. PubMed ID: 25259514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.
    Kawatkar SP; Gagnon M; Hoesch V; Tiong-Yip C; Johnson K; Ek M; Nilsson E; Lister T; Olsson L; Patel J; Yu Q
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3248-3252. PubMed ID: 27265257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Amino-3-substituted-6-[(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl]imid azo[1,2-a]pyridines as a novel class of inhibitors of human rhinovirus: stereospecific synthesis and antiviral activity.
    Hamdouchi C; de Blas J; del Prado M; Gruber J; Heinz BA; Vance L
    J Med Chem; 1999 Jan; 42(1):50-9. PubMed ID: 9888832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors.
    Majer P; Collins JR; Gulnik SV; Erickson JW
    Protein Sci; 1997 Jul; 6(7):1458-66. PubMed ID: 9232647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.